Comment How about the linked article? (Score 5, Informative) 140
Let me give you a brief summary of TFA:
- Some cancers have IDH1, IDH2 mutations that change cellular metabolism
- This drug is the first targeting the IDH2 enzyme that has been tested in humans
- 6 out of 7 patients whose disease (leucemia) had the specific IDH2 mutations had "objective response" to the drug, ie the disease burden was reduced. Note, this does not mean cure.
Now, this is obviously good news, in the same spirit as previous targeted agents like vemurafenib, erlotinib, trastuzumab, crizotinib, especially since it concerns a new aspect of cellular functioning (metabolism). It's too early to say whether the drug will have long lasting impact, but we'll know more after phase II/III trials. It does seem promising.
For patients with AML or MDS and documented IDH2 mutation, the study (NCT01915498) is still recruiting in several centers around the US and in Paris/France (Institut Gustave-Russy). More information can be found in clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/results?term=NCT01915498&Search=Search).